Amgen Enbrel Clears FDA For Psoriasis Supplemental Indication; Detailing Begins Immediately
This article was originally published in The Pink Sheet Daily
Executive Summary
The company calls on 3,500 dermatologists for its psoriatic arthritis indication; Amgen hopes to increase promotion to 9,000 dermatolgists.
You may also be interested in...
Enbrel DTC Campaign Should Restore Growth In Psoriasis Market, Amgen Says
The company had been sponsoring a disease awareness program while working to bring a branded spot back on the air after an FDA warning letter targeted an initial ad.
Enbrel DTC Campaign Should Restore Growth In Psoriasis Market, Amgen Says
The company had been sponsoring a disease awareness program while working to bring a branded spot back on the air after an FDA warning letter targeted an initial ad.
Amgen Expects Enbrel Prefilled Syringes To "Blunt" Humira Competition
The company will launch the new delivery device by the end of November, one month ahead of schedule. Enbrel's growth has been driven by performance in psoriasis, where the product holds the vast majority of market share among biologics.